SCHEMBL3633959

SCHEMBL3633959

CCC(C)Oc1cccc(NCc2c[nH]nc2-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
PPARA Q07869 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
LMNA P02545 1/20 0.35
CASR P41180 2/20 0.35
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
FRK P42685 1/20 0.35
CAMK2B Q13554 1/20 0.35
CAMK2G Q13555 1/20 0.35
CAMK2D Q13557 1/20 0.35
PTGER2 P43116 1/20 0.35
MAP3K5 Q99683 1/20 0.34
PTGES O14684 1/20 0.34
KCNH2 Q12809 1/20 0.34
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3638187 0.92 MAPT (0.37) MAPTGAAHDAC1HDAC8HDAC6
SCHEMBL3635323 0.92 MAPT (0.40) MAPTGAAHDAC1HDAC8HDAC6
SCHEMBL3800645 0.91 GAA (0.40) MAPTGAAHDAC1HDAC8HDAC6
SCHEMBL3636789 0.87 GAA (0.37) MAPTGAAHDAC1HDAC8HDAC6
SCHEMBL3636746 0.86 HDAC1 (0.51) MAPTGAAHDAC1HDAC8HDAC6
SCHEMBL3640361 0.83 FLT1 (0.40) MAPTGAAHDAC1HDAC8HDAC6
SCHEMBL3636635 0.83 GRK2 (0.47) MAPTGAAHDAC1HDAC8HDAC6
SCHEMBL4919177 0.82 RXFP1 (0.46) MAPTGAAMAP3K5
SCHEMBL3636214 0.82 MAPT (0.49) MAPTGAAPPARANPSR1LMNA
SCHEMBL3640392 0.81 POLB (0.36) MAPTGAANPSR1LMNAROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
CN-101687790-B Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) ABBVIE INC 2015-02-11 CN disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
CN-101687790-A Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) ABBOTT GMBH & CO KG 2010-03-31 CN disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 MAPT 572/4885GAA 2566/4885HDAC1 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.